To detect the presence of point mutations in a small section of the mutS homolog2 (MSH2) gene in both healthy and affected persons treated at the General Hospital of the State of Sonora, a 353 base pair section of the MSH2 gene was amplifi ed and sequenced from six persons affected by hereditary nonpolyposis colorectal cancer and from 19 healthy persons. The affected persons did not show the mutations reported in the scientifi c literature; however, six healthy persons were heterozygote and mutant-allele carriers. The heterozygote condition implies that carriers are candidates for the development of colorectal cancer. However, it is important to know the family medical history when investigating hereditary mutations.
Introduction
Modern biomedical research has reached great advances in the knowledge of the genetic mechanisms involved in the major illnesses, in the improvement of treatments, and consequently in the primary healthcare. and PMS2. [1] [2] [3] [4] Our present treatments do not allow us to win the battle at the most advanced stages, but the information generated has contributed to the understanding of the cellular processes and to develop good detection methods to be able to use more effi cient therapy. However, healthy people are unaware of the possibility for them to be carriers of genes that predispose them to colorectal cancer, independent of the family background.
According to Fishel et al., [1] HNPCC patients have a microsatellite instability caused by a transition mutation in an mutS homolog 2 (MSH2) intron, in the 2020 position of the cDNA, in which healthy persons have an adenine and the affected persons have a guanine. Recently, MedinaArana et al. [5] reported another point mutation in MSH2 also responsible for microsatellital instability in HNPCC patients and located 63 base pairs upstream of the Fishel et al. [1] mutation. This new mutation is the replacement of an adenine by a cytosine. Epigenetic factors such as hypermethylation are also believed to be responsible for genetic instabilities that cause colorectal cancer. [6] Because of the absence of molecular studies that give an idea of the relationship among the DNA modifi cations 
Materials and Methods
Over 10 Because HNPCC is a hereditary illness, we believed it important to include close relatives, but it was not possible to obtain a complete family history because of refusal or contact diffi culties. It was only possible to obtain blood samples from the daughters of two patients.
In total, the survey included 25 persons; six affected, two healthy daughters, and 17 healthy unrelated persons.
The samples were analyzed to determine the presence of a transition mutation of A to G [1] or the transversion mutation of A to C. [5] All participants in the survey give their informed consent and the protocol of the survey was The polymerase chain reactions (PCR) were done using the puReTaq Ready-to-Go PCR beads (GE Healthcare, Little Chalfont, UK) in 25 μl fi nal volume. A 353-base pair fragment of the MSH2 gene that may contain the two reported mutations related to HNPCC [1, 5] was amplifi ed with primers 16324: 5'-CGCGATTAATCATCAGTG-3'
and 16340: 5'-GGACAGAGACATACATTTCTATC-3'. [1] The reactions were done with 0.05 μg of DNA and 5 pmol of each primer following the PCR conditions reported by
Fishel et al. [1] The PCR products were visualized in 2% agarose gels with TAE buffer, stained with ethidium bromide, and were sequenced by Macrogen (Seoul, Korea). Sequence ambiguities were resolved with Chromas Pro ver 1.41.
A BLAST analysis at GenBank corroborated the identity of the sequences. by Fishel et al. [1] This incidence is 31% of the healthy persons analyzed [ Figure 2 ] with ages from 21 to 50
Results

All the PCR reactions
years. Fifty percent of those heterozygotes have a family medical history of cancer. None of the 25 persons analyzed were heterozygotes for the point mutation reported by Medina-Arana et al. [5] 
Discussion
Because mutations in the MSH2 are responsible at least for a third of the HNPCC cases, [3] we expected to fi nd some affected patients with the reported mutations [1, 5] but they had the healthy version of the gene in both tissue When a person is a heterozygote, as found in this study, it means that one of the parents inherited the mutant allele. Median-Arana et al. [5] mentioned that if a heterozygote person develops a cancer tumor, the tumor cells are homozygotes and as the tumor develops the proportion of heterozygote cells will drop.
An important aspect is that mutations responsible for HNPCC are dominant and had 70%-90% of penetrance. [5] That means that a healthy heterozygote person has a 10%-30% probability to not develop the illness. If people know their genetic condition in advance, they will have the opportunity to get medical advice and monitoring early and pay special attention to the fi rst abnormal symptoms. 
